Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||E7107 + GSK3203591 + MS023|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|E7107||E 7107|E-7107||E7107 is a derivative of Pladienolide D, which inhibits assembly of the spliceosome specifically by binding to SF3B1, thereby inhibiting splicing of pre-mRNA and cell-cycle progression (PMID: 27622333, PMID: 31558432).|
|GSK3203591||GSK591|EPZ015866||GSK3203591 inhibits PRMT5, potentially resulting in decreased tumor cell growth (PMID: 29946150).|
|MS023||MS023 inhibits type I protein arginine methyltransferases (PRMTs), which may lead to anti-tumor activity (PMID: 26598975).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|SRSF2 P95H||chronic myeloid leukemia||sensitive||E7107 + GSK3203591 + MS023||Preclinical - Cell culture||Actionable||In a preclinical study, E7107, MS023, and GSK3203591 triple combination potently inhibited survival of a chronic myeloid leukemia cell line with knockin SRSF2 P95H in culture (PMID: 31408619).||31408619|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|